24/7 Patient Assistance: 760-405-8205

Barbara J. Gitlitz, MD

Medical Oncologist

Write a review
Doctor's profile photo

Request a call back

Conditions Treated Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Pleural Mesothelioma Testicular Mesothelioma

  • Bio & Insurance Information

    Dr. Barbara Gitlitz is a medical oncologist in Los Angeles, California. She got her medical degree from Stony Brook University School of Medicine and did an internship at UCLA Medical Center. Dr. Gitlitz completed a residency at Cedars-Sinai Medical Center and a fellowship at UCLA Medical Center. She is certified in medical oncology and has more than 20 years of experience. Currently Dr. Gitlitz is affiliated with Keck Hospital of USC and USC Norris Cancer Hospital.

  • Education & Training


    Stony Brook University School of Medicine

    Medical School


    UCLA Medical Center



    Cedars-Sinai Medical Center



    UCLA Medical Center


  • Board Certifications

    American Board of Internal Medicine - Oncology

  • Hospital & Practice

    Keck Hospital of USC - Medical Center

    Languages: English/Spanish

    (323) 442-8500

    1500 San Pablo St

    Los Angeles, California 90033

    Read More

    USC Norris Comprehensive Cancer Center

    Languages: English/Spanish

    (323) 865-3000

    1441 Eastlake Avenue

    Los Angeles, California 90033

    Read More
  • Publications & Memberships

    Dr. Barbara J. Gitlitz has contributed to 3 publications.

    Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

    Carter, C. A.,Rajan, A.,Keen, C.,Szabo, E.,Khozin, S.,Thomas, A.,Brzezniak, C.,Guha, U.,Doyle, L. A.,Steinberg, S. M.,Xi, L.,Raffeld, M.,Tomita, Y.,Lee, M. J.,Lee, S.,...; Ann. Oncol.. 2016 Jan 24.

    See more >>

    Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWO.

    Lara, P. N.,Moon, J.,Redman, M. W.,Semrad, T. J.,Kelly, K.,Allen, J.,Gitlitz, B.,Mack, P. C.,Gandara, D. R.; Clin Lung Cancer. 2015 Oct 27.

    See more >>

    I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sen

    Ou, S. H.,Greenbowe, J.,Khan, Z. U.,Azada, M. C.,Ross, J. S.,Stevens, P. J.,Ali, S. M.,Miller, V. A.,Gitlitz, B.; Lung Cancer. 2015 Mar 05.

    See more >>


    American Association for Cancer Research

    American Society of Clinical Oncology

    International Association for the Study of Lung Cancer

    Southwestern Oncology Group